» Articles » PMID: 8386772

Structure Determination of Antiviral Compound SCH 38057 Complexed with Human Rhinovirus 14

Overview
Journal J Mol Biol
Publisher Elsevier
Date 1993 Apr 5
PMID 8386772
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

SCH 38057 (1-[6-(2-chloro-4-methoxyphenoxy)-hexyl]imidazole hydrochloride) is a new, water-soluble antiviral compound that has inhibitory activities against a number of picornavirus infections. The structure of the human rhinovirus 14 (HRV14) complex with SCH 38057 was determined at 3.0 A resolution by single-crystal diffraction techniques using synchrotron X-radiation. SCH 38057 was found to bind at the innermost end of the hydrophobic pocket within the capsid protein VP1, a locus of binding of other antipicornaviral agents; however, the complex differs from previously reported complexes in two important aspects. It leaves a considerable volume near the entrance to the binding pocket unoccupied. In addition, the alterations in the conformation of the VP1 polypeptide are similar to, but more extensive than those observed in HRV14 complexes with other antiviral agents. Although only 9 amino acids of VP1 have close contacts with the SCH 38057 molecule (within 3.6 A), at least 36 amino acids from both VP1 and VP3 have significantly altered conformations (C alpha movement > 0.5 A versus native). The structures of complexes of HRV14 with SCH 38057 and WIN 51711 are compared. Aromatic ring interactions between picornavirus capsid residues and antiviral inhibitors are proposed to be among the major determinants for positioning of these compounds.

Citing Articles

Rhinovirus Inhibitors: Including a New Target, the Viral RNA.

Real-Hohn A, Blaas D Viruses. 2021; 13(9).

PMID: 34578365 PMC: 8473194. DOI: 10.3390/v13091784.


Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.

Yi G, Lapelosa M, Bradley R, Mariano T, Dietz D, Hughes S PLoS One. 2013; 8(9):e72205.

PMID: 24039745 PMC: 3765159. DOI: 10.1371/journal.pone.0072205.


Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

Lapelosa M, Arnold G, Gallicchio E, Arnold E, Levy R J Mol Biol. 2010; 397(3):752-66.

PMID: 20138057 PMC: 2940250. DOI: 10.1016/j.jmb.2010.01.064.


Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Arnold G, Velasco P, Holmes A, Wrin T, Geisler S, Phung P J Virol. 2009; 83(10):5087-100.

PMID: 19279101 PMC: 2682058. DOI: 10.1128/JVI.00184-09.


Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

Smith A, Geisler S, Chen A, Resnick D, Roy B, Lewi P J Virol. 1998; 72(1):651-9.

PMID: 9420270 PMC: 109419. DOI: 10.1128/JVI.72.1.651-659.1998.